Pfizer + Seagen — Building an Oncology Powerhouse

Pfizer's $43-billion acquisition of Seagen (closed December 2023) added leading antibody-drug conjugate (ADC) technology and cancer medicines including Padcev, Adcetris, and Tukysa, becoming one of pharma's largest oncology franchises. The integration is a central Pfizer strategy story covered by science journalists, biotech creators, and health-policy writers globally — including in India where cancer care remains a critical unmet need.